China announced on Thursday that it had granted conditional marketing authorization for its first self-developed COVID-19 vaccine.
The inactivated vaccine, which got the approval from the National Medical Products Administration (NMPA), is developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated with Sinopharm.
The interim results of its phase-3 clinical trials show 79.34 percent efficacy against COVID-19, meeting the standards of the World Health Organization and the NMPA, according to a press conference by the State Council joint prevention and control mechanism against COVID-19.
Peru suspended Chinese COVID vaccine trails of Chinese govt owned Sinopharma. The vaccine side effects resulted in Guillain-Barre syndrome, a very rare disease in which the immune system attacks the nerves.
Long process of due diligence, cabinet finally approves to order 1.1 million doses of Sinopharma Vaccine whose effectiveness is in 70s and which is almost nowhere else approved because of its hazy documentation. Even China approved it only yesterday.
Oxford – UK,
Sinopharma – China,
moderna – US,
Pfizer/BioNTech – German+Chinese
With its efficacy is 79%, Sinopharm announced on December 30 that phase three trials of the vaccine showed it was 79% effective.Pfizer and Moderna have 95% efficacy, while AstraZeneca’s 70% efficacy in full trials increased to 90%.
Pfizer vaccine needs to be stored at -75˚C and Moderna’s at -20 degree Celsius, which are deal breakers for Pakistan as it lacks the logistical capability to roll out these vaccines on a massive scald to its population. On the other hand, the Sinopharm candidates can be stored at standard refrigerator temperatures of 2˚C to 8˚C (36˚F to 46˚F).
UAE, Bahrain, and now Pakistan have granted emergency use of the vaccine for frontline workers. Morocco is also arranging for the Sinopharm jab.
China approved the emergency use of COVID-19 vaccines in June, targeting groups with high risks of infection. By the end of November, more than 1.5 million doses of Chinese COVID-19 vaccines had been distributed for emergency use, and 60,000 vaccinated people have traveled abroad to high-risk regions, with no severe adverse reactions reported, Zeng said.
On Dec. 15, China officially launched a vaccination program for this winter-spring period targeting a number of key groups, including those engaged in handling imported cold-chain products, customs officers, medical workers and people working in public transport and fresh markets. In the past 15 days, the number of doses of vaccination among the key groups exceeded 3 million.
“The 3 million vaccine doses, plus the previous 1.5 million doses, fully prove that Chinese vaccines are safe,” Zeng noted.